Table III. Recommended Endocrine Therapy.
| FTM-transsexual individuals | ||
|---|---|---|
| Suppression of original sex hormones | Replacement of the hormones of desired sex* | |
| Oral lynestrenol 5 mg daily (Orgametril®) | Testosterone ester 125-250 mg every two weeks IM (Sustanon®) | |
| Oral medroxyprogesterone acetate 5-10 mg daily | Testosterone Undecanoate 1000 mg every 10-12 weeks | |
| (Provera®, Farlutal®) | IM (Nebido®) | |
| GnRH-analogue: triptoreline 3.75 mg (Decapeptyl®) | Testosterone 100 mg transdermally daily (Androgel®, | |
| IM monthly or goserelin 3.6 mg (Zoladex®) SC monthly | Testim®, Testogel®) | |
| MTF-transsexual individuals | ||
| Suppression of original sex hormones | Replacement of the hormones of desired sex* | |
| Oral cyproterone acetate 50-100 mg daily (Androcur®) | Oral 17β-estradiol valerate 2-4 mg daily (Progynova®) | |
| Transdermal estradiol 1.5-3 mg daily (Estreva®, Oestrogel®) | ||
| Transdermal 17β-estradiol 50-100 µg daily (Climara®, | ||
| Dermestril®, Vivelle Dot®) | ||
Bold: substances preferred by the Ghent Gender Team.
*: continued after SRS.